Bausch Health to buy Durect for $63M upfront; Fulcrum’s Ph1b sickle cell datanews2025-07-29T14:58:21+00:00July 29th, 2025|Endpoints News|
Is the Sarepta mess what a political FDA looks like?news2025-07-29T13:31:27+00:00July 29th, 2025|Endpoints News|
Health tech is bucking healthcare investing trendsnews2025-07-29T13:00:34+00:00July 29th, 2025|Endpoints News|
FDA approves PTC’s rare genetic disease drugnews2025-07-29T12:58:43+00:00July 29th, 2025|Endpoints News|
Endpoints livestream: Is the Sarepta mess what a politicized FDA looks like?news2025-07-29T12:58:05+00:00July 29th, 2025|Endpoints News|
Exelixis axes late-stage plans for TKI drug in head and neck cancer as Q2 earnings disappointnews2025-07-29T12:28:27+00:00July 29th, 2025|Endpoints News|
Novo Nordisk downgrades sales expectations by 5% to 7%news2025-07-29T11:32:34+00:00July 29th, 2025|Endpoints News|
Artbio attracts $132M as its alpha radioligand program moves into the clinicnews2025-07-29T11:30:57+00:00July 29th, 2025|Endpoints News|
AstraZeneca reports revenue growth, pipeline tweaks as it ponders price cuts, direct-to-patient salesnews2025-07-29T11:07:58+00:00July 29th, 2025|Endpoints News|
Updated: Merck announces $3B in cost cutsnews2025-07-29T10:30:36+00:00July 29th, 2025|Endpoints News|
